title: Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients.
abstract: Tardive dyskinesia (TD) is a side effect of chronic antipsychotic medication exposure. Abnormalities in dopaminergic activity in the nigro-striatal system have been most often suggested to be involved because the agents that cause TD share in common potent antagonism of dopamine D(2) receptors (DRD2). Thus, a number of studies have focused on the association of dopamine system gene polymorphisms and TD, with the most consistent findings being an association between TD and the Ser9Gly polymorphism of the DRD3 gene and the TaqIA site 3' of the DRD2 gene. The DRD4 gene codes for the third member of the D(2)-like dopamine receptor family, and the variable number tandem-repeat polymorphism in exon 3 of DRD4 has been associated with TD. However, other polymorphisms have not been thoroughly examined. In this study, we investigated five polymorphisms spanning the DRD4 gene and their association with TD in our European Caucasian sample (N=171). Although the exon 3 variable number tandem repeat was not associated with TD, haplotypes consisting of four tag polymorphisms were associated with TD in males. This study suggests that DRD4 may be involved in TD in the Caucasian population, although further replication studies are needed.
authors.affiliation: Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
authors.forename: C C
authors.initials: CC
authors.lastname: Zai
authors.forename: A K
authors.initials: AK
authors.lastname: Tiwari
authors.forename: V
authors.initials: V
authors.lastname: Basile
authors.forename: V
authors.initials: V
authors.lastname: De Luca
authors.forename: D J
authors.initials: DJ
authors.lastname: Müller
authors.forename: N
authors.initials: N
authors.lastname: King
authors.forename: A N
authors.initials: AN
authors.lastname: Voineskos
authors.forename: G
authors.initials: G
authors.lastname: Remington
authors.forename: H Y
authors.initials: HY
authors.lastname: Meltzer
authors.forename: J A
authors.initials: JA
authors.lastname: Lieberman
authors.forename: S G
authors.initials: SG
authors.lastname: Potkin
authors.forename: J L
authors.initials: JL
authors.lastname: Kennedy
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004409:Dyskinesia, Drug-Induced / Q000235:genetics*; D005091:Exons; D018628:Gene Dosage; D006801:Humans; D011110:Polymorphism, Genetic; D050638:Receptors, Dopamine D4 / Q000235:genetics*; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics*; D020080:Tandem Repeat Sequences
chemical_list: D014150:Antipsychotic Agents; D050638:Receptors, Dopamine D4